Skip Navigation LinksHome Research report list Pharma & Healthcare Pharmaceutical Breast Cancer Market Report: 2013 Edition
Breast Cancer Market Report: 2013 Edition
Format : Pdf (Instant Download)
Date: 18, June 2013 | Pages: 55
Electronic Access - Single User License
USD 800
Electronic Access - Corporate User License
USD 1100
Hard Copy - Mail Delivery
USD 875

Riding on the back of evolving technological environment, the global healthcare and pharmaceutical industry is now surmounting new acmes. The growth of the respective sector is further filliped by the increasing number of health related issues surfacing on account of changing lifestyle and incessantly evolving surroundings. To cater to the necessity of better healthcare options and the unmet needs within the some of the underlying segments, related companies are coming up with novel and improved diagnostic technologies and treatment therapies, especially in the field of breast cancer treatment.


‘Cancer’ is the result of any mutation or abnormal changes in the genes which are responsible for regulating the growth of cells and keeping them healthy. The tumor formed due to cancer can be either ‘benign’ (not dangerous) or ‘malignant’ (potentially dangerous). ‘Breast cancer’ is a malignant tumor that has developed from cells in the breast. Typically breast cancer either begins in the cells of the lobules (milk-producing glands), or the ducts (the passages that drain milk from the lobules to the nipple).


The stages of breast cancer are crucial as they only determine the type of treatment method and the extent to which the disease can be cured. On the diagnosis front, mammography is believed to diagnose 85% to 90% of breast cancers in women over 50, and is capable of discovering a lesion one to four years before a lump can be felt. In case of patients with dense breast tissue, breast implants or patients who are breastfeeding, mammography cannot produce clear images; therefore, in such cases, ultrasound or MRI is recommended. Biopsy is used for the diagnosis of breast cancer once a lesion is detected in screening. For treatment of breast cancer, the first method to be used is surgical, followed by hormone therapy, chemo therapy or radiation therapy.


After lung cancer, breast cancer is the 2nd most prevalent type of cancer and 5th most common cause of cancer deaths on global scale. Over one million new cases of breast cancer are diagnosed every year world over.


The present report offers a comprehensive analysis of the global breast cancer diagnosis and treatment market with focus on regions like the US, India and Brazil including the revenue build of two major drugs in the coming years. Furthermore, market dynamics such as the industry trends and development, the underlying growth drivers and major issues faced by the industry are elicited. On the contention front, the market is personified by the intense competition in terms of research and development of novel therapeutic molecules, diagnostics technology application and pricing of the product. The leading players operating in the industry include Hologic, J&J and Siemens AG which are also profiled in this report.


1. Breast Cancer: Overview

1.1 Types of Breast Cancer
1.2 Risk Factors
1.3 Symptoms of Breast Cancer
1.4 Diagnosis and Treatment of Breast Cancer
1.4.1 Breast Cancer Screening and Diagnostic Measures
1.4.2 Breast Cancer Treatment Regime


2. Market Size

2.1 Breast Cancer Statistics
-New Cases
-Estimated Deaths

2.2 Breast Cancer Market Structure
- Therapeutics Market
-Diagnostics Market
-Market Segmentation

2.2.1 Regional Breast Cancer Markets
-The US

2.3 Breast Cancer Therapeutics Model


3. Market Dynamics

3.1 Industry Trends and Developments

3.1.1 Successive Clinical Trials and Product Development

3.2 Growth Drivers

3.2.1 Increasing Prevalence of Cancer
3.2.2 Increasing Use of Tobacco and Alcohol
3.2.3 Expanding Obese Population
3.2.4 Rising Demand for Better Healthcare Options
3.2.5 Growing Female Population (+45 Years)
3.2.6 Higher Spending on Medicines

3.3 Challenges

3.3.1 Rising Costs of Treatment
3.3.2 Stringent Regulatory Measures
3.3.3 Adverse Effects of the Treatment
3.3.4 Mounting Price Pressure


4. Competitive Landscape


5. Company Profiles

5.1 Hologic, Inc.

5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
-Focus on Research & Development
-Business Expansion via Strategic Acquisitions

5.2 Johnson & Johnson

5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
-Research & Development Activities
-Financial Risk Minimization

5.3 Siemens AG

5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
-Accelerating R&D Activities
-Focus on Healthcare Segment

List of Charts

Types of Breast Cancer
Various Biopsy Methods
Global Oncology Sales (2009-2014E)
Breast Cancer Therapeutics Market (2011 and 2020E)
Global Breast Cancer Predictive Diagnostic and Drug Technologies (2011 and 2016E)
The US Beast Imaging Systems Market (2011 and 2016E)
India’s Breast screening Market (2011 and 2018E)
Number of Cancer Cases Worldwide (2007-2011)
Global Breast Cancer Incidences (2010 & 2030E)
Growth in Worldwide Obese Population (2004-2012F)
Global Female Population, +45 Years (2008-2014F)
Global Spending on Medicines (2006-2016E)
Global Spending on Medicine Share by Region (2006-2016E)
The US Spending on Medicine (2007-2016E)
Japan’s Spending on Medicine (2007-2016E)
Hologic’s Revenue Share by Business Segment (2012)
Hologic’s Revenues and Net Income (2008-2012)
Johnson & Johnson’s Revenue Share by Business Segments (2012)
Johnson & Johnson’s Revenues and Net Earnings (2008-2012)
Siemens AG’s Revenue Share by Business Segments (2012)
Siemens AG’s Revenues and Net Income (2008-2012)


List of Tables

Stages of Breast Cancer
New Cases of Breast Cancer and Estimated Deaths in America (2013E)
America’s Female Breast Cancer Statistics (2013E)
Global Breast Cancer Market Size by Segment (2011 and 2016E)
Total US Tomosynthesis Market Opportunity
NeuVax/E75 (nelipepimut) Sales – Breast Cancer Market Size Model (2017E-2020E)
Ganetespib Metastatic Breast Cancer Revenue Build in the US (2016E-2020E)
Breast Cancer Drugs & Agents in Clinical Development
Estimated Cancer Cases in the US (2012)
Estimated Cancer Deaths in the US (2012)
Patients Worldwide Waiting for Better Treatment Options (2011)
FDA Regulation of Medical Devices
Comparison of Adjuvant Chemotherapy Tests in Breast Cancer
J&J’s R&D Statistics (2011 & 2012)

One can also purchase any particular sections from this report. Please send us an email to with your order details.
About Us    |    PRESS RELEASES    |    RESEARCH REPORTS    |    Contact Us    |    PRIVACY POLICY    |    REFUND POLICY
@ Copyright 2014 Koncept Analytics Pvt Ltd. All Rights Reserved. Web Developed By Vision IT Consultants Pvt Ltd.